iBio Advances Bispecific Antibody for Pulmonary Hypertension in Heart Failure, Targets Q3 2026 Development Candidate
核心洞察
iBio is developing a selective bispecific antibody (搜索) targeting activin A, myostatin (搜索) (GDF8 (搜索)), and GDF11 (搜索) to treat pulmonary hypertension (搜索) associated with heart failure with preserved ejection fraction (搜索) (PH-HFpEF (搜索)).
The company expects to declare an optimized development candidate in the third quarter of 2026, validated for potency, selectivity, manufacturability, and in vivo efficacy.
iBio's approach aims to address multiple core drivers of PH-HFpEF (搜索) biology simultaneously while avoiding safety issues linked to broader TGF-β (搜索) ligand blockade.
iBio, Inc. (NASDAQ:IBIO) announced plans to advance a novel bispecific antibody (搜索) program targeting pulmonary hypertension (搜索) associated with heart failure with preserved ejection fraction (搜索) (PH-HFpEF (搜索)), with the company expecting to declare a development candidate in the third quarter of 2026.
The AI-driven biotech company is engineering a selective bispecific antibody (搜索) designed to block activin A, GDF8 (搜索) (myostatin (搜索)), and GDF11 (搜索) to reduce cardiac fibrosis (搜索), reverse pulmonary vascular remodeling, and improve whole-body functional capacity. The approach is intentionally designed to avoid safety issues linked to broader TGF-β (搜索) ligand blockade.
Strategic Pipeline Expansion
"Targeting PH-HFpEF (搜索) represents an important step for our company and reflects conviction in our platform, program, and understanding of the biology," said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. "We believe our antibody approach has the potential to address key drivers of disease biology in an area where patients continue to face substantial unmet need."
iBio's bispecific approach is designed to target multiple core drivers of PH-HFpEF (搜索) biology simultaneously, addressing what the company identifies as a gap among currently approved PH-HFpEF therapies. The company expects to declare the optimized bispecific antibody (搜索) development candidate for PH-HFpEF in the third quarter of calendar 2026, validated for potency, selectivity, manufacturability, and in vivo efficacy, before entering IND-enabling activities.
Addressing Significant Unmet Need
Heart failure with preserved ejection fraction (搜索) (HFpEF (搜索)) is a heterogeneous syndrome in which the heart continues to pump with a preserved ejection fraction but becomes impaired in its ability to relax and fill properly. HFpEF accounts for approximately half of all heart failure cases and is closely associated with obesity (搜索), diabetes (搜索), hypertension (搜索), and aging.
Pulmonary hypertension (搜索) associated with HFpEF (搜索) (PH-HFpEF (搜索)) represents a clinically severe subtype linked to pulmonary vascular remodeling, reduced functional capacity, and poor prognosis. While current therapies have benefited many patients, there remains a significant unmet need for treatments that more directly modify the underlying drivers of disease.
HFpEF (搜索) affects millions worldwide, and iBio's long-term vision is to build a family of therapies targeting core cardiometabolic pathways across the spectrum of cardiometabolic disease.
Selective Mechanism of Action
iBio's bispecific antibody (搜索) program targets three closely related ligands—myostatin (搜索) (GDF8 (搜索)), GDF11 (搜索), and activin A—that sit at the intersection of skeletal muscle health, metabolic function, cardiac fibrosis (搜索), and vascular remodeling. Because these pathways can drive disease in both obesity (搜索)/weight-loss-related dysfunction and PH-HFpEF (搜索), iBio believes that the same selective mechanism of action may address both areas.
The company emphasizes selective blockade that spares BMP9 (搜索)/BMP10 (搜索) and activin B (搜索) to limit bleeding and hemodynamic risks while preserving metabolic effects. Internal cell and rodent HFpEF (搜索) data show antifibrotic and cardiac benefit signals, though human translation remains to be proven.
External Validation and Market Interest
Management highlighted recent external validation of the activin pathway, pointing to GSK's agreement to acquire 35Pharma (搜索) for $950 million and clinical data from Merck (搜索)'s sotatercept program as support for pursuing more selective activin-pathway targeting approaches.
Cory Schwartz, Ph.D., iBio's Director of Research and Early Development, described the convergence between obesity (搜索) and PH-HFpEF (搜索) biology as involving shared ligands—activin A, myostatin (搜索) (GDF8 (搜索)), and GDF11 (搜索)—and shared tissue targets including pulmonary vasculature, myocardium, and skeletal muscle.
Platform Integration
iBio's obesity (搜索)-focused pipeline has been built around a thesis that morbidity and mortality in obesity are driven less by weight alone and more by downstream functional decline and organ damage, including cardiometabolic disease and fibrosis. The company's existing programs include IBIO-600, which targets myostatin (搜索) and GDF11 (搜索) to preserve or restore skeletal muscle during weight loss, and IBIO-610 (搜索), which targets activin E (搜索) with the goal of selectively reducing adiposity, particularly visceral fat.
As iBio expanded its work on the TGF-β (搜索) superfamily, the company concluded that the biology underlying functional decline in obesity (搜索) overlaps with mechanisms implicated in PH-HFpEF (搜索), leading to the strategic expansion into cardiopulmonary applications.